Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Marcum Microcap Conference 2015
26 slides from Nemaura Medical's conference presentation, Jun 1, 2015
Slide 1: Marcum Microcap Conference
nemaura Marcum Microcap Conference New York, 27-28 May 2015 Dr Faz Chowdhury CEO
Slide 2: Company Summary
nemaura Company Summary Focusing exclusively on minimally-invasive transdermal diagnostic technologies which can be applied to a broad range of medical conditions. These diagnostic technologies can be inverted to enable drug delivery of a large number of drug molecules. Common set of IP used to cove
Slide 3: Early Market Validation
nemaura Early Market Validation This first product is known as sugarBEAT™ and consists of three parts: - Askin prep-kit and a class Ila medical device - apatch — applied to the skin, and - Amobile phone app. Several grants previously awarded for sugarBEAT™ by Innovate UK cumulatively exceed $1.6m. L
Slide 4: Management Team with Successful Track Record
nemaura Management Team with Successful Track Record Dr. Dewan Fazlul Hoque Chowdhury: President, Chief Executive Officer and Director of NMRD since incorporation. Responsible for product development, innovation, and commercialization. Also founder of Microneedle Technologies (set up Oct. 2009) and
Slide 5: Management Team with Successful Track Record (cont'd)
nemaura Management Team with Successful Track Record (cont'd) Bashir Timol: * Commercial Director of NMRD and Trial Clinics Limited since Incorporation and Dermal Diagnostics Limited from October 2013. + Responsible for financial planning, business development and corporate strategies. * Over 10 yea
Slide 6: nedical
nemauranedical = 5 se -2f go gos D5 ces 2c $ g os a eo Sos 2s nes ae a i A 8 3s H 5 2a ee ; 2 e =s H S 56 i) i O34 ges so : 5 <2 Are ' 5 § 2 ! 3 oo as j ° Sit 35 = ; id 6 “Go £ 1 C. fae g, Binenrrencas e000 Teeeenanmnceaucanaiaass 52 = £0 F f| 2 4 oC ‘ =f ° ie H 2 Se 3 H 3 ° ano 3 : EY 6 8 ed < —4 i
Slide 7: Investment Thesis
nemaura Investment Thesis Large addressable market Firstto market with minimally invasive, continuous glucose monitoring commercial product Leverageable technology can be used to address other markets “Lean organization” with outsourced manufacturing and marketing minimizes cash burn Experienced man
Slide 8: Market Opportunity for sugarBEAT™
nemaura Market Opportunity for sugarBEAT™ Estimated prevalence of diabetes for adults aged 20-79 worldwide [Diabetes UK] * 382 million in 2012, 592 million by 2035 * 175 million people currently have undiagnosed Type II Diabetes 10% of diabetics are Type |, and 90% are Type ll Cost of Diabetes manag
Slide 9: sugarBEAT™ Product
nemaura sugarBEAT™ Product Consists of three parts; a disposable patch (“Patch”), bluetooth enabled device (“Device”) and smart phone app (“App”) Minimally-invasive and continuous (up to 4 readings an hour). Patch affixed to arm, leg or abdomen which in turn is connected to device. Device measures g
Slide 10: sugarBEAT™ Product
nemauramecical sugarBEAT™ Product 1. Affix Patch 5. Transfer Data 2. Extract Glucose Reverse lontophoresis’ 4. Display Results 3. Measure Glucose Level 3. Device read: glucose le and trans data to App via blue tooth 10
Slide 11: sugarBEAT™ Product - Device Illustration
nemaura sugarBEAT™ Product-— Device Illustration
Slide 12: sugarBEAT™ Product - Illustration of App
nemauranedical sugarBEAT™ Product - Illustration of App B.) doy summory 12
Slide 13: Technology - sugarBEAT™
nemaura Technology - sugarBEAT™ Technical basis of reverseiontophoresis: Works by passing a mild current across the skin that is barely perceptible, or non-perceptible. This current pulls the glucose out of interstitial fluid, which is found just below the top layer of skin, into a reservoirin the p
Slide 14: Technology - sugarBEAT™
nemaura Technology - sugarBEAT™ Historical basis of reverse iontophoresis: There are over 20 independently published public papers, generated over a twenty year period, that confirm the clinical efficacy of the reverse iontophoresis technique. Reverse iontophoresis has also previously received both
Slide 15: Patents
nemaura Patents Patents granted: Region Purpose Expires Europe, China, Hong Kong Patches for Reverse lontophoresis: Watch Device patent June 2028 describing the construction of patches and watch device for extracting glucose from the skin non-invasively. Europe, USA, Canada Method for non-invasively
Slide 16: Comparative Clinical Data to Date
nemaura Comparative Clinical Data to Date Clinical Data in Type | andl Diabetics: 100 patient day: 30 patients, 3 or 4 visits, 12— 14 hour device wear time Paired MARD Data Data Pearson data in in Correlation points Zone A | Zone B Invasive | Dexcom 4634 | 10.80% | 84.50% | 15.10% 0.94 CGM Ga* Invas
Slide 17: sugarBEAT™ Product Evolution
nemaura sugarBEAT™ Product Evolution Clinical Prototype Device Version One Device Version Two Clinical prototype used for current clinical trials + Device Version One to be launched Q4 2015 Device Version Two is expected to eliminate need for daily finger prick hence be fully non invasive, and antic
Slide 18: Key Milestones for sugarBEAT™ Initial Product Launch in Asia and Middle East
nemaura Key Milestones for sugarBEAT™ Initial Product Launch in Asia and Middle East Commercial Developments: Milestone # Months From Target Completi CE Approval [application already submitted] 3 Manufacturing and Mass Production of sugarBEAT™ device and patches 6 sugarBEAT™ mobile Phone app — devel
Slide 19: Target Market Analysis for sugarBEAT™
nemaura Target Market Analysis for sugarBEAT™ Market Analysis — Type 1 diabetics*: (lee Number of Diabetics Market Penetration of sugarBEAT’ Year 2014 Year 2015 Year 2019 | Year 2015 Year 2019 Middle East 363,000 364,815 372,166 1.00% 12.00% 396,000 (Saudi) 397,980 405,999 425% 13.50% i) 82,360 84,0
Slide 20: Pricing Strategy for sugarBEAT™
nemauranedical Pricing Strategy for sugarBEAT™ Price comparison between sugarBEAT™ product, a popular invasive glucose monitoring device (the Dexcom Platinum) and finger prick testing using test strips and glucose monitor Finger Prick” Dexcom Platinum Ongoing Annual Cost" Finger Prick Calibration To
Slide 21: Sales & Distribution for sugarBEAT™
nemauranedical Sales & Distribution for sugarBEAT™ To minimize fixed cost commitments, we will appoint specialist partners in each territory responsible for sales management, marketing and distribution under one roof. We have specific criteriain selecting specialist partners: Track record in sales o
Slide 22: Assumptions for sugarBEAT™
nemauranedical Assumptions for sugarBEAT™ Mi n/ K = thousand ($ US Dollar)/ Year to March3' Number of global markets Total number of CGM devices sold 23K 116K 386K 498K 798K Total number of patches sold 1 mil. 27mil. 110mil. 212mil. 314 mil. Change in CGM devices price 0% 0% 0% 0% 0% Change in patch
Slide 23: Assumptions for sugarBEAT™
nemauranedical Assumptions for sugarBEAT™ Mi n/ K= thousand ($ US Dollar)/ Year to March3' Capital expenditures — Machinery -- -- -- -- 41 Mil. Capital expenditures — Others -- -- 1 Mil. 2Mil. 3 Mil. Research & development-— specific 8 Mil. 8 Mil. 1 Mil. -- -- Research & development-— general -- --
Slide 24: Financial Forecast for sugarBEAT™
nemaura Financial Forecast for sugarBEAT™ Revenue 10 85 270 461 694 Cost of sales u 42 136 244 366 Gross profits 5) 43 134 217 328 Expenses Sales and marketing 1 5 10 19 22 General and administration 1 2 2 3 3 Finance -- -- -- -- -- Depreciation -- -- -- -- 1 Research and development 8 8 2 2 3 Total
Slide 25: Fundraising and Use of Proceeds
nemauranedical Fundraising and Use of Proceeds Planned amount to be raised in 2015: $5 million to $15 million Use of proceeds: Projects /Items 25
Slide 26: Contacts
nemauraic Contacts Dr D F Chowdhury Bashir Timol Nemaura Medical Inc., Nemaura Medical Inc., Holywell Park Holywell Park Ashby Road Ashby Road Loughborough Loughborough Leics, Leics, LE113AQ LE113AQ UK UK Tel: +44 1509222912 Tel: +44 1509222912 Email: faz.chowdhury@nemaura.com Email: bashir.timol@ne